Corinna Brander
Nurse Practitioner · Norfolk, VANPI 1881139434
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.4%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by TG Therapeutics, Inc. at 25.9% of the total. Reporting peaked in 2024 at $3,610 and has fallen 77.2% since, to $823 in 2025. Among nurse practitioner clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 219 payments — averaging $41.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- TG Therapeutics, Inc.$2K
- Banner Life Sciences, LLC$2K
- Biogen$1K
- AstraZeneca$691
- Genentech USA, Inc.$663
- Sanofi$641
- plus $2K from 14 others
What the payments were for
- Consulting fees$1,50017%
- Speaking & faculty fees$2,10023%
- Travel & lodging$3664%
- Food & beverage$4,28947%
- Education$8009%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| TG Therapeutics, Inc. | 12 | $2,345 |
| Banner Life Sciences, LLC | 3 | $1,762 |
| Biogen | 84 | $1,376 |
| AstraZeneca | 9 | $691 |
| Genentech USA, Inc. | 22 | $663 |
| Sanofi | 7 | $641 |
| EMD Serono, Inc. | 16 | $448 |
| AbbVie | 30 | $257 |
| Novartis | 14 | $244 |
| Eisai Inc. | 5 | $216 |
| Lundbeck LLC | 2 | $143 |
| Pfizer | 5 | $109 |
| Amgen | 2 | $30 |
| Bristol Myers Squibb | 2 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Livanova USA, Inc. | 1 | $16 |
| Irhythm Technologies, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| SK Life Science, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,055 in reported general payments places this provider in the 95th percentile of 2,166 nurse practitioner providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TecfideraDimethyl Fumarate | 38 | $377,096 |
| VumerityDiroximel Fumarate | 34 | $295,084 |
| AubagioTeriflunomide | 24 | $217,618 |
| Teriflunomide | 38 | $149,120 |
| CopaxoneGlatiramer Acetate | 22 | $139,166 |
| Kesimpta PenOfatumumab | 11 | $131,204 |
| Dimethyl Fumarate | 65 | $130,491 |
| Plegridy PenPeginterferon Beta-1a | 14 | $115,780 |
| Dalfampridine ErDalfampridine | 72 | $44,699 |
| Nurtec OdtRimegepant Sulfate | 11 | $19,752 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $17,097 |
| Baclofen | 228 | $6,675 |
| Gabapentin | 354 | $6,356 |
| Modafinil | 46 | $5,255 |
| Carbamazepine | 28 | $1,455 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenTecfidera, Vumerity | $1,376 | $672,18072 claims |
| SanofiAubagio | $641 | $217,61824 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $15 | $139,16622 claims |
| PfizerNurtec Odt | $109 | $19,75211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,166 nurse practitioner providers in Virginia.
Other nurse practitioner in Norfolk
- Elizabeth WilletteNorfolk$58K
- Deborah QuinnNorfolk$11K
- Terrinda AlstonNorfolk$10K
- Miriam Galan-DejesusNorfolk$9K
- Ursula PretoriusNorfolk$6K
- Samantha FoxGate City$207K
- Mikel GrayCharlottesville$174K
- Kevin BrigleRichmond$166K
- Denese GomesRichmond$126K
- Ashley CarmenAlexandria$99K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.